In the Late 1990s, Compounds That Functioned as Leukotriene Receptor

In the late 1990s, compounds that functioned as leukotriene receptor antagonists were approved for the treatment of asthma. The first such drug, zafirlukast, inhibits the actions of a major receptor for leukotrienes, known as CYSLTR1 (cysteinyl leukotriene receptor 1) . One would predict that patients on this drug would show:

A) Enhanced mucus production
B) Enhanced vascular permeability
C) Increased accumulation of leukocytes in the lung
D) Reduced mast cell activation
E) Reduced bronchoconstriction